Cargando…

Renovascular and renoprotective properties of telmisartan: clinical utility

Chronic kidney disease (CKD) affects approximately 26 million adults in the United States and millions of others are at increased risk. Type 2 diabetes and hypertension are the two main causes of CKD. Blood pressure control is critical to slow the progression of CKD. Despite adequate control, howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladino, Marco, Schulman, Ivonne Hernandez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108769/
https://www.ncbi.nlm.nih.gov/pubmed/21694926
_version_ 1782205371176189952
author Ladino, Marco
Schulman, Ivonne Hernandez
author_facet Ladino, Marco
Schulman, Ivonne Hernandez
author_sort Ladino, Marco
collection PubMed
description Chronic kidney disease (CKD) affects approximately 26 million adults in the United States and millions of others are at increased risk. Type 2 diabetes and hypertension are the two main causes of CKD. Blood pressure control is critical to slow the progression of CKD. Despite adequate control, however, patients continue to progress to end-stage renal disease. Angiotensin receptor blockers (ARBs) are commonly used in the management of hypertension and CKD and have been shown to exert renoprotective effects that are in addition to, but independent of, blood pressure lowering. Telmisartan is a long-acting ARB with pharmacological properties beyond blockade of the angiotensin II type 1 receptor, including activation of the peroxisome proliferator activated receptor-γ (PPAR-γ). This article reviews the beneficial renal and vascular protective effects of telmisartan.
format Online
Article
Text
id pubmed-3108769
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31087692011-06-21 Renovascular and renoprotective properties of telmisartan: clinical utility Ladino, Marco Schulman, Ivonne Hernandez Int J Nephrol Renovasc Dis Review Chronic kidney disease (CKD) affects approximately 26 million adults in the United States and millions of others are at increased risk. Type 2 diabetes and hypertension are the two main causes of CKD. Blood pressure control is critical to slow the progression of CKD. Despite adequate control, however, patients continue to progress to end-stage renal disease. Angiotensin receptor blockers (ARBs) are commonly used in the management of hypertension and CKD and have been shown to exert renoprotective effects that are in addition to, but independent of, blood pressure lowering. Telmisartan is a long-acting ARB with pharmacological properties beyond blockade of the angiotensin II type 1 receptor, including activation of the peroxisome proliferator activated receptor-γ (PPAR-γ). This article reviews the beneficial renal and vascular protective effects of telmisartan. Dove Medical Press 2010-03-16 /pmc/articles/PMC3108769/ /pubmed/21694926 Text en © 2010 Ladino and Schulman, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Ladino, Marco
Schulman, Ivonne Hernandez
Renovascular and renoprotective properties of telmisartan: clinical utility
title Renovascular and renoprotective properties of telmisartan: clinical utility
title_full Renovascular and renoprotective properties of telmisartan: clinical utility
title_fullStr Renovascular and renoprotective properties of telmisartan: clinical utility
title_full_unstemmed Renovascular and renoprotective properties of telmisartan: clinical utility
title_short Renovascular and renoprotective properties of telmisartan: clinical utility
title_sort renovascular and renoprotective properties of telmisartan: clinical utility
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108769/
https://www.ncbi.nlm.nih.gov/pubmed/21694926
work_keys_str_mv AT ladinomarco renovascularandrenoprotectivepropertiesoftelmisartanclinicalutility
AT schulmanivonnehernandez renovascularandrenoprotectivepropertiesoftelmisartanclinicalutility